Cibus (CBUS) Shares Outstanding (2016 - 2026)
Cibus (CBUS) posted Shares Outstanding (Entity) of $54.6 million for Q4 2025, little changed sequentially from $54.5 million in Q3 2025, and up 135.14% YoY from $23.2 million in Q4 2024.
Cibus (CBUS) Shares Outstanding (2016 - 2026) Analysis & Trends
Cibus has reported Shares Outstanding (Entity) for 10 years, with the latest figure at $54.6 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 135.14% year-over-year to $54.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54.6 million (up 135.14% YoY) and the FY2025 annual result came in at $54.6 million, up 135.14% from the prior year.
- Shares Outstanding (Entity) was little changed at $54.6 million in Q4 2025 per CBUS's latest filing, from $54.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $54.6 million in Q4 2025 and troughed at $743264.0 in Q1 2021.
- A 5-year average of $16.0 million and a median of $8.2 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2021 and 2024: Shares Outstanding (Entity) increased 4.61% in 2021, then soared 2389.15% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $775480.0 in 2021, then grew by 25.97% to $976896.0 in 2022, then jumped by 955.85% to $10.3 million in 2023, then soared by 125.14% to $23.2 million in 2024, then jumped by 135.14% to $54.6 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $54.6 million, $54.5 million, and $41.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | 76.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.76 Mn |
| Dec 31, 2025 | 45.76 Mn |
| Sep 30, 2025 | 52.93 Mn |
| Jun 30, 2025 | 41.62 Mn |
| Mar 31, 2025 | 35.05 Mn |
| Dec 31, 2024 | 23.22 Mn |
| Sep 30, 2024 | 23.59 Mn |
| Jun 30, 2024 | 21.85 Mn |
| Mar 31, 2024 | 20.86 Mn |
| Dec 31, 2023 | 10.31 Mn |
| Sep 30, 2023 | 16.64 Mn |
| Jun 30, 2023 | 6.14 Mn |
| Mar 31, 2023 | 988,139.00 |
| Dec 31, 2022 | 919,951.00 |
| Sep 30, 2022 | 935,689.00 |
| Jun 30, 2022 | 933,270.00 |
| Mar 31, 2022 | 840,402.00 |
| Dec 31, 2021 | 749,515.00 |
| Sep 30, 2021 | 745,594.00 |
| Jun 30, 2021 | 743,987.00 |